F Fogt - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

F Fogt

Showing results (61-70 of 63) with videos related to

Pageof 7

Sort By:

You have reached the last page of results.This site can display upto 63 results.

Applied Immunohistochemistry & Molecular Morphology : AIMM|June 9, 2001

Expression of survivin, YB-1, and KI-67 in sporadic adenomas and dysplasia-associated lesions or masses in ulcerative colitisF Fogt, C Poremba, K Shibao, et al.

Human Pathology|April 4, 2000

Distinction between dysplasia-associated lesion or mass (DALM) and adenoma in patients with ulcerative colitisF Fogt, S J Urbanski, M E Sanders, et al.

The American Journal of Gastroenterology|January 5, 2002

An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitisJ D Lewis, G R Lichtenstein, R B Stein, et al.

Pageof 7

Search research articles

Showing results (61-70 of 63) with videos related to

Sort By:

Pageof 7

You have reached the last page of results.This site can display upto 63 results.

Applied Immunohistochemistry & Molecular Morphology : AIMM|June 9, 2001

Expression of survivin, YB-1, and KI-67 in sporadic adenomas and dysplasia-associated lesions or masses in ulcerative colitisF Fogt, C Poremba, K Shibao, et al.

Human Pathology|April 4, 2000

Distinction between dysplasia-associated lesion or mass (DALM) and adenoma in patients with ulcerative colitisF Fogt, S J Urbanski, M E Sanders, et al.

The American Journal of Gastroenterology|January 5, 2002

An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitisJ D Lewis, G R Lichtenstein, R B Stein, et al.

Pageof 7